Cyprotex Highlights - March 2020
Both our Alderley Park (UK) and Watertown (USA) sites are operational and continue to serve our clients during this difficult time.
Read Evotec’s latest statement on the current
COVID-19 situation:
Learn more about microelectrode array technology (MEA) and the role it plays in early toxicology assessment.
Read our comprehensive 14 page review article.
Early CNS Liability
Read our latest blog to learn more about our recent research poster - originally planned for SOT 2020.
The poster highlights the advantages of using a combined in vitro screening approach for effectively identifying early CNS liability.
Read the latest news from parent company, Evotec:
- Evotec SE reports 2019 financial results and corporate update
- Ildong gains access to Evotec’s INDiGO platform to accelerate the development of various proprietary projects.
- Evotec's partner Forge Therapeutics Inc. announces research collaboration with Roche to develop novel antibiotic
- Global collaboration launched in fight against tuberculosis
- Read Evotec's new whitepaper on
'Drug Abuse Liability Assessment'
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com